EX-99.2 3 seg910.txt SEGMENT RESULTS SEGMENT INFORMATION TECHNE CORPORATION AND SUBISIDARIES (in thousands of $'s, except per share data) Increase (Decrease) Fiscal 2011 From Fiscal 2010 -------------------- ------------------ First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 67,945 100% 1,411 Cost of sales 15,241 22% 2,340 ------- -------- ------- Gross margin 52,704 78% (929) Gross margin percentage 77.6% SG&A expense 7,552 11% (486) R&D expense 6,619 10% 465 Amortization expense 170 -- (70) Interest income (847) (1%) 321 Other non-operating ex., net 257 -- (405) ------- -------- ------- 13,751 20% (175) ------- -------- ------- Earnings before income taxes 38,953 58% (754) Income taxes 12,580 19% (355) ------- -------- ------- 26,373 39% (399) ======= ======== ======= Diluted earnings per share 0.71 Weighted average diluted shares outstanding 37,107 BIOTECHNOLOGY (1) (in thousands of $'s) Increase (Decrease) Fiscal 2011 From Fiscal 2010 -------------------- ------------------ First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 54,141 100% 2,445 Intersegment sales (7,491) 177 ------- ------- 46,650 2,622 Cost of sales 11,689 22% 1,804 Intersegment sales (7,578) 20 ------- ------- 4,111 1,824 ------- -------- ------- Gross margin 42,539 78% 798 Gross margin percentage 78.4% SG&A expense 4,583 8% (151) R&D expense 6,421 12% 465 Amortization expense 170 -- (70) Interest income (581) (1%) 190 Exchange loss/gain (8) -- (10) ------- -------- ------- 10,585 19% 424 ------- -------- ------- Pretax result 31,954 59% 374 ======= ======== ======= (1) Includes R&D Systems' Biotechnology Division, BiosPacific, Inc. and R&D China R&D SYSTEMS EUROPE (in thousands of British pounds) Increase (Decrease) Fiscal 2011 From Fiscal 2010 -------------------- ------------------ First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 10,571 100% (310) Cost of sales 5,561 53% 500 ------- -------- ------- Gross margin 5,010 47% (810) Gross margin percentage 47.4% SG&A expense 1,188 11% (3) Interest income (52) -- 35 Exchange loss/(gain) (323) (3%) (234) ------- -------- ------- 813 8% (202) ------- -------- ------- Pretax result 4,197 39% (608) ======= ======== ======= R&D SYSTEMS EUROPE (in thousands of $'s) Increase (Decrease) Fiscal 2011 From Fiscal 2010 -------------------- ------------------ First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 16,391 100% (1,447) Cost of sales 8,621 53% 326 ------- -------- ------- Gross margin 7,770 47% (1,773) Gross margin percentage 47.4% SG&A expense 1,842 11% (110) Interest income (81) -- 62 Exchange loss/(gain) (497) (3%) (352) ------- -------- ------- 1,264 8% (400) ------- -------- ------- Pretax result 6,506 39% (1,373) ======= ======== ======= HEMATOLOGY (in thousands of $'s) Increase (Decrease) Fiscal 2011 From Fiscal 2010 -------------------- ------------------ First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 4,904 100% 236 Cost of sales 2,509 51% 190 ------- -------- ------- Gross margin 2,395 49% 46 Gross margin percentage 48.8% SG&A expense 328 7% (42) R&D expense 198 4% -- Interest income (53) (1%) 19 ------- -------- ------- 473 10% (23) ------- -------- ------- Pretax result 1,922 39% 69 ======= ======== ======= CORPORATE AND OTHER (2) (in thousands of $'s) Increase (Decrease) Fiscal 2011 From Fiscal 2010 ----------- ------------------ First First Quarter Quarter ------- ------- Interest income 132 (50) Rental income 123 42 ------- ------- 255 (8) SG&A expense 799 (183) Other-Building expenses 556 8 Other-Equity Investment losses 329 (9) ------- ------- 1,684 (184) ------- ------- Pretax result (1,429) 176 ======= ======= (2) Unallocated corporate expenses and Techne's share of losses by Hemerus Medical, LLC and Nephromics, LLC.